Company reaches $1.75B valuation as contractors adopt system-level autonomy across complex infrastructure projects

SAN FRANCISCO, Feb. 4, 2026 — Bedrock Robotics, a leader in autonomous construction technology, today announced it has raised $270 million in Series B funding co-led by CapitalG and the Valor Atreides AI Fund, with participation from Xora, 8VC, Eclipse, Emergence Capital, Perry Creek Capital, NVentures (NVIDIA’s venture capital arm), Tishman Speyer, Massachusetts Institute of Technology, Georgian, Incharge Capital, C4 Ventures, and others. This round brings Bedrock’s total funding to over $350 million. The funding will accelerate Bedrock’s mission to transform how general contractors build, from deploying individual autonomous machines to orchestrating fully connected fleets that reshape productivity and safety.

The new funding follows a period of rapid growth for Bedrock. The company emerged from stealth in July 2025 with $80 million in Seed and Series A funding, and in November completed a large-scale supervised autonomy deployment for mass excavation on a 130-acre manufacturing site.

“The construction industry is being asked to build more than it can deliver,” said Boris Sofman, co-founder and CEO of Bedrock Robotics. “Contractors are pulled across competing priorities with the same limited workforce and equipment. This funding helps us scale our development and deployments as we mature autonomy capabilities and the tools for contractors to leverage them. It’s a first step toward a future where entire fleets operate as coordinated systems, fundamentally changing how modern contractors plan, staff, and execute work.”

The industry needs nearly 800,000 workers over the next two years to keep up with demand, with retirements further widening the labor gap. Project backlogs climbed to more than eight months as of December 2025. Against this backdrop, contractors are exploring Bedrock’s autonomy systems across a range of applications spanning port infrastructure, industrial facilities, data centers, and large-scale earthmoving operations across multiple states. On a manufacturing campus in central Texas, Champion Site Prep is currently using the Bedrock Operator to explore how autonomous systems could complement the crews they have today.

“The speed and scale of what’s coming into this region is unlike anything we’ve seen before—automotive, aerospace, AI infrastructure—and these projects don’t wait,” said Trey Taparauskas, President and CEO at Champion Site Prep. “What Bedrock is building will multiply what our crews are capable of. It’s not just about one autonomous machine; it’s the potential to rethink how we coordinate our entire fleet, keep machines running longer, reduce idle time, and improve safety and work zone awareness. That frees up our best people to supervise and strategize so we can take on even more.”

“Hundreds of billions of dollars are flowing into construction, but the workforce simply isn’t there to meet the moment,” said Derek Zanutto, General Partner at CapitalG. “Every major hyperscaler and developer is grappling with how to compress project schedules when labor constraints keep pushing them out. Bedrock’s technology is built on world-class autonomy expertise, and we believe it will unlock the construction velocity this moment requires.”

“What stands out about Bedrock is execution—delivering milestone after milestone with precision and capital efficiency that’s uncommon in this space,” said Antonio Gracias, Founder, CEO, and Chief Investment Officer of Valor Equity Partners. “The companies defining the future of AI, energy, and advanced manufacturing all share a common need: they have to build faster than ever before. We’re confident Bedrock is the team to make that possible.”

In addition to new funding, Bedrock recently expanded its leadership team with key hires. Vincent Gonguet joined as Head of Evaluation, having previously led AI safety and alignment at Meta for all Llama models. John Chu also joined as Head of People after serving in the same role for Waymo’s engineering teams, overseeing headcount growth of 400% while the company expanded globally. The company is targeting its first fully operator-less excavator deployments with customers in 2026—a milestone in autonomous capability for such complex, articulated machines.

About Bedrock Robotics
Founded in 2024, Bedrock Robotics is building the future of autonomous construction. Based in San Francisco, the company is led by former Waymo engineers who helped pioneer the systems that made fully autonomous vehicles a reality on public roads. Now they’re bringing that same deep expertise to construction equipment, developing technology that will enable contractors to improve safety, expand capabilities, and compress schedules to meet growing demand at scale. Bedrock is working alongside leading general contractors to co-develop autonomous solutions to retrofit machines like excavators, bulldozers, and loaders with a vision to make fully autonomous fleets standard on job sites across the country. To learn more, visit www.bedrockrobotics.com.

About CapitalG
CapitalG, Alphabet’s independent growth fund, invests in generational companies transforming the fields of enterprise infrastructure, security, and data; fintech; and consumer services and marketplaces. CapitalG partners with growth stage companies in their transition from startup to scale up through hands-on assistance and connections to Google’s engineering, product, marketing, sales and people operations experts worldwide. More than 3500 Googlers and Alphabet leaders have engaged with CapitalG portfolio companies, including Stripe, CrowdStrike, Databricks, Duolingo, Freshworks, Monzo, UiPath and Zscaler, among others. Learn more at https://capitalg.com.

About Valor Equity Partners
Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development.  For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale.  Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries.  For more information on Valor Equity Partners, please visit www.valorep.com.

About Atreides Management
Atreides Management is a crossover investment firm with a long-term perspective, investing in technology and consumer companies across public and private markets. From seed to pre-IPO to publicly listed, Atreides’ model is designed to support mission-driven entrepreneurs throughout a company’s lifecycle. For more information, please visit www.atreidesmgmt.com.

About Champion Site Prep 
Founded in 1985, Champion Site Prep is one of Central Texas’s largest and most experienced commercial earthwork contractors, with more than 3,000 completed projects spanning industrial, multifamily, education, healthcare, retail, and municipal development. As an employee-owned company, Champion is committed to professional-quality excavation and site preparation—coupled with the latest technologies—while maintaining the loyalty and teamwork that have driven nearly four decades of success. To learn more, visit www.idigdirt.com.

Media Contact:
Anjelica Sarkar 
[email protected] 

SOURCE Bedrock Robotics

Accel leads the round, joined by WillowTree Ventures, MVP Ventures, as Fibr AI turns websites into adaptive experience systems built for modern traffic—human and AI alike

SAN FRANCISCO, Feb. 4, 2026 — Fibr AI, the company building the Agentic Web Experience Layer to unlock revenue, today announced $7.5 million in Seed funding led by Accel, with participation from WillowTree Ventures and MVP Ventures, alongside prominent Fortune 100 operatorsas angel investors and advisors.

Founded by Ankur “AJ” Goyal and Pritam Roy, Fibr AI reimagines high-traffic consumer-facing websites as an adaptive system. While marketing has become dynamic, most websites still operate under the outdated assumption that the same experience should work for every visitor, even as traffic arrives with very different intent from ads, search, recommendations, and AI systems. This results in broken journeys, wasted spend, and lost revenue. Fibr closes this gap by turning websites into context-aware experiences that continuously adapt and optimize for every visitor, human or AI.

“Marketing has become intelligent everywhere except the website,” said Ankur Goyal, CEO and co-founder of Fibr AI. “We’re building the Agentic Web, where every URL operates as a living experience system that understands context and responds in real time—for humans, cohorts, and even AI agents. The website stops being a passive destination and becomes an active part of the growth stack for Marketers and CMOs.”

“Most websites today still run on infrastructure built years ago,” said Prayank Swaroop, Partner at Accel. “CMS platforms are effective at publishing content, but not at understanding context or adapting in real time. That gap is becoming more visible in conversational discovery, like ChatGPT and LLM-driven advertising, where users arrive with high intent and ready to act. The website can’t just be a destination—it has to respond immediately and intelligently. What’s compelling about Fibr is that it brings AI agents directly into the experience layer, enabling websites to understand context and adapt in real time. It consolidates what used to require multiple tools, agencies, and large teams, into one system, making true one-to-one experiences possible at scale.”

To learn more about Fibr AI, visit: https://fibr.ai/.

About Fibr AI

Fibr AI is an agentic website optimization platform that transforms high-traffic consumer-facing websites into adaptive, revenue-driving experiences for both human visitors and AI-Agents — by turning every URL into an intelligent agent. The company is already trusted by Fortune 50 banks and global enterprises across banking, financial services, and healthcare.

Press Contact
Tory Kurpeski
[email protected] 

SOURCE Fibr AI

Monster.com founder returns with AI-powered platform to disrupt the industry he created

CHARLESTOWN, R.I., Feb. 4, 2026 — Boomband, an AI-native talent marketplace founded by Monster.com creator and entrepreneur Jeff Taylor, today announced Boomband’s upcoming launch and the closing of a $4.0 million seed round led by Boston Seed with participation from New England VC’s Slater Technology Fund, Rogue Venture Partners and Service Provider Capital.

“Having worked for Jeff Taylor at Monster.com, I was excited to invest in Jeff’s latest innovation in the human capital industry,” said Peter Blacklow, Managing Director at Boston Seed Capital. “Boomband stood out because of the strength of its founding team and understanding of the evolving job market. Jeff’s background in shaping the earliest and most influential digital employment platform gives him a unique lens on today’s AI dynamics and the changing workforce. That perspective drove how Boomband has been developed, and at launch it positions the company for ambitious growth.”

Boomband is building the alternative for millions of people sick of being ghosted by algorithms and buried by outdated hiring systems, and for the recruiters drowning in applications that lead to nowhere. The company is building a platform where humans are seen in full – not reduced to keyword-matching resumes or backward-facing profiles.

Why Boomband? Because the System is Broken.

The hiring system today is noise and volume, inundated with endless resumes and thousands of applications. Recruiters are drowning in unqualified candidates and job seekers are burning out from rejection.

“LinkedIn is where careers go to scroll. We’re building Boomband for discovery,” said Jeff Taylor, Founder and CEO of Boomband. “If you’ve ever applied for a job and heard nothing back or felt invisible because your story didn’t fit the mold, this is for you. With 7.5 million Americans out of work, people are rethinking what they want from their lives, how they define balance, and how they show up in their careers. Sending a resume into a black hole isn’t working anymore. It’s dehumanizing, inefficient, and it’s costing people real opportunities.”

Boomband flips the script:

• No more cold applications. Players (job seekers) express interest in verified jobs. Scouts (companies) create Job Signals – both private, AI-powered outreach designed for quality, not quantity.
• No more resumes. Players build Dossiers – a 360-degree view of a person’s potential. Dynamic, multimedia profiles that show the full story: work, projects, passions, values, goals.
• No more job boards. The Arena is Boomband’s real-time discovery environment, where talent and opportunity meet based on mutual alignment.

Boomband is designed to put humans, not keywords, at the center of talent discovery.

“We’re not trying to fix the resume. We’re replacing it,” said Taylor. “The world doesn’t need more job boards. It needs a new way for people and companies to find each other – based on who they really are.

Boomband is launching first in New England, partnering with companies across tech, healthcare, financial services, and manufacturing. Early Scout partners include UWill, Leader Bank, CRH, Zus Health, Rochester Electronics, Wood MacKenzie, Talent Retriever, Quanterix, South Shore Health, Ionic and Maverick Technology Partners.

Boomband is currently accepting early adopters, welcoming both Players and Scouts ahead of its public launch in March 2026. Visit www.boomband.com to create your Dossier, develop Job Signals, and start finding opportunities.

“Everyone deserves to be seen,” said Taylor. “And as we build the right system, they will be.”

About Boomband
Boomband is a human-first, AI-native talent platform that connects people and opportunity through dynamic Dossiers, AI-powered matching, and a new discovery engine called the Arena. Founded by Monster.com creator Jeff Taylor, Boomband replaces outdated resumes and job boards with tools built for a world where talent is today. Backed by top seed investors and ready to use by early partners across industries, Boomband is launching first in New England before expanding nationwide in 2026. For more information, visit www.boomband.com. Brand launch video: Let’s band together!

Media Contact
Connor Burke
[email protected]
315.427.4079

SOURCE Boomband

WHITE PLAINS, N.Y., Feb. 4, 2026 — Manor Park Ventures, a family-backed real estate investment and development firm, today announced the opening of its new headquarters at Switch2 Ten, the newly redeveloped former NYNEX building located at 10 County Center Road in White Plains, New York.

The relocation marks an important milestone for the firm as it continues to expand its development platform and strengthen its presence throughout the Northeast. The new headquarters provides Manor Park Ventures with a modern, flexible environment designed to support collaboration, strategic growth, and long-term operations.

“Our move to Switch2 Ten reflects the evolution of Manor Park Ventures and the direction we are heading,” said Marc Weil, President of Manor Park Ventures. “As our portfolio and partnerships continue to grow, it is important to establish a headquarters that matches the scale, professionalism, and ambition of our firm.”

The firm’s new office features a thoughtfully designed layout with dedicated collaboration areas. Its central White Plains location offers convenient access to Westchester County Airport, regional rail service, key institutional partners, and major transportation corridors.

“This new space allows us to better support our partners, investors, advisors, and development teams while continuing to build a platform designed for durability and long-term growth,” added Weil.

Manor Park Ventures is actively advancing a pipeline of multifamily and mixed-use developments across high-growth markets in the Northeast and Southeast United States, including Knoxville, Tennessee, and Huntsville, Alabama. Supported by family capital and a disciplined, principal-driven investment approach, the firm also evaluates select investments beyond real estate, including technology and specialty operating businesses.

About Manor Park Ventures
Manor Park Ventures is a family-backed real estate investment and development firm focused on the acquisition, development, and operation of strategic real estate assets. Concentrating on opportunistic multifamily development projects throughout the Northeast and Southeast United States, the firm partners with developers and family offices that share a long-term investment philosophy and commitment to value creation.

Contact:
Johanna Greystone
[email protected]
(914) 200-0592

SOURCE Manor Park Ventures

Led by Santé Ventures, the funding will enable beHuman to expand its network of health insurance partners and end customers nationally

MIAMI, Feb. 4, 2026 — beHuman, a physician-led preventive care platform focused on improving early cancer detection for underserved populations, today announced it has raised a $4 million seed round led by Santé Ventures, with participation from DHVP.io. The funding will support beHuman’s expansion beyond its current footprint in the north and southeast, accelerating its mission to make early cancer screening more accessible to patients nationwide.

While early cancer detection has become an increasingly active area of innovation within healthcare, many existing solutions primarily serve affluent, highly engaged consumers. beHuman offers a vertically-integrated solution that is designed to reach a different, and often far larger, population: insured patients who rarely or never receive recommended screenings due to geographic barriers, limited access to care, administrative complexity, or longstanding mistrust of the healthcare system.

“Early detection dramatically improves outcomes, yet millions of insured Americans are still diagnosed too late simply because the system never reaches them,” said Steve Yaskin, Founder and CEO of beHuman. “beHuman was built to meet patients where they are, especially those in rural and underserved communities, by removing friction, restoring trust, and making prevention simple, accessible, and life-saving.”

beHuman integrates virtual clinical care, advanced diagnostic testing, and longitudinal health data access to proactively identify cancer risk and guide patients through appropriate screening pathways. Its agentic AI platform automates key administrative workflows such as eligibility verification, scheduling, chart review, and follow-up, which reduces the burden on clinicians while preserving rigorous, physician-led care.

Importantly, beHuman’s model directly addresses patient concerns around data privacy and misuse, which are especially prevalent in underserved communities. The platform is designed with strict data governance, transparency, and clinical oversight to ensure patient information is used solely to support care.

Early results show that beHuman’s cancer detection rates exceed national averages. By engaging patients earlier in the disease timeline, beHuman is able to uncover risk that would otherwise go undetected until far later stages. Furthermore, the service is covered by most major insurance plans, eliminating cost as a barrier and enabling patients to participate in preventive care without a significant out-of-pocket expense.

Santé Ventures brings deep experience backing healthcare companies that modernize care delivery and improve outcomes at scale. “beHuman is addressing one of healthcare’s most persistent gaps, late cancer detection among populations the system consistently misses,” said Kevin Lalande, Founding Managing Director and Chief Investment Officer at Santé Ventures. “The team’s combination of physician leadership, thoughtful AI automation, and focus on trust and access positions them to deliver meaningful impact nationwide.”

With the new funding, beHuman will:

• Expand into additional states
• Deepen partnerships with leading diagnostic laboratories
• Advance its agentic AI platform to further streamline preventive care workflows
• Scale its physician-led virtual care teams to serve more patients efficiently

As beHuman grows, the company remains focused on its core principle: prevention works best when it is equitable, trusted, and easy to access. To learn more about beHuman, please visit www.behuman.health.

About beHuman
beHuman is a physician-led preventive care platform using AI to make early cancer detection accessible at scale. By combining virtual care, advanced diagnostics, and automated workflows, beHuman helps underserved and under-screened patients identify cancer risk earlier and navigate screening with confidence. The platform is covered by most insurance plans and currently operates across multiple U.S. states.

About Santé Ventures
Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with over $1 billion in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally enabled healthcare services. Recent Santé successes include Laminar (Johnson & Johnson), Farapulse (Boston Scientific), Healthcare Highways – CerpassRx (Nomi Health), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Bristol Myers Squibb), and Explorys (IBM Corp). Santé invests nationally and has offices in Austin, TX and Boston, MA. For more information, please visit www.sante.com.

Media Contact
Ryan Walker
R.J. Walker & Co.
[email protected]

SOURCE beHuman

$52M equity adds to previously announced $165M Series A

New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group

SPRING HOUSE, Pa., Feb. 4, 2026 — Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.

New investor Andreessen Horowitz (a16z) joined Third Arc Bio’s existing world-class investor syndicate to further validate the company’s approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio’s Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.

“Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease,” said Jorge Conde, General Partner at a16z. “The company’s platforms, combined with a team that has repeatedly translated complex immunology into approved medicines, reflect a rigorous, patient-driven approach to building biologics that can improve both efficacy and safety across oncology and immune-mediated disease.”

Since its launch in 2022 with seed financing from Omega Funds, Third Arc Bio has assembled a highly experienced team with a proven track record of drug discovery and development, alongside an innovative platform and a pipeline of multispecific antibodies. The company’s lead asset, ARC101, is a bispecific T cell engager targeting CLDN6 currently in Phase 1 dose escalation in patients with advanced solid tumors.

“This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies,” said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio. “By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need.”

Third Arc Bio’s approach to I&I is anchored by its ARCTag (Tethered Agonist) Platform, which leverages multispecific antibodies to localize immune modulation directly to sites of disease. This targeted activity represents a meaningful advance beyond conventional systemic autoimmune therapies, offering the potential for enhanced efficacy and therapeutic index.

About Third Arc Bio
Third Arc Bio is a clinical stage biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells. The lead program ARC101, is a bispecific T cell engager currently being evaluated in a Phase 1 trial for cancer patients with solid tumors expressing CLDN6. The company’s drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging novel technologies that power a pipeline of high value therapeutics. The Third Arc Bio platforms include a solid tumor ARCStim Platform and an immunology & inflammation (I&I) ARCTag Platform that offers precision immune regulation to achieve superior efficacy and safety. To learn more, visit www.thirdarcbio.com.

Media Contact
Peg Rusconi, Deerfield Group
[email protected] 

SOURCE Third Arc Bio

Fuels the company’s Collaborative Intelligence^™ platform growth

FORT LAUDERDALE, Fla., Feb. 4, 2026 — SynthBee, Inc., a stealth start-up pioneering its Collaborative Intelligence^™ (CI^™) platform, today announced the completion of $100 million in funding with Crosspoint Capital Partners, LP (Crosspoint Capital), following its initial $20 million seed funding and an additional $80 million secured last week. Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets. 

This investment accelerates SynthBee’s mission of building its proprietary CI^™ technology platform, expansion into new markets, and continued investment in talent. SynthBee’s current and future customers span medical technology and healthcare, aerospace and defense, advanced manufacturing, automotive, financial services, and other key technology and media industries.

“At Crosspoint, we were blown away by the power of the business case for the customer. The value proposition and time-to-value cannot be ignored,” said Andre Fuetsch, Managing Director, Crosspoint Capital. “We’re incredibly excited about what the SynthBee team has created, its cohort of industry-leading customers, and the scale of the opportunity ahead. The team has invented a new way for organizations to harness intelligence at speed and with confidence. SynthBee’s differentiated CI^™ platform is precisely the kind of bold, grounded innovation Crosspoint [Capital] wants to back for the long term.” 

SynthBee’s mission is to help enterprises across key markets radically accelerate innovation across the product and technology lifecycles, from concept to manufacturing. The Company was founded by Rony Abovitz, the entrepreneur behind MAKO Surgical (acquired by Stryker for $1.65 billion) and Magic Leap, both recognized for redefining their categories in surgical robotics and spatial computing/XR. SynthBee’s CI^™ platform aims to bring that same level of innovation and impact to a broad range of businesses in the United States and around the free world.

“SynthBee’s customers operate in mission-critical, high-performance areas across complex, regulated markets,” said Rony Abovitz, President and CEO at SynthBee. “Our proprietary CI^™ platform empowers businesses to solve complex scientific, engineering, design, compliance and creative challenges at extreme speed, with high accuracy, high privacy, high reliability, under human control and with clear auditability. This investment enables us to deepen our work with businesses across numerous vertical markets that require secure, high-reliability systems for their most important engineering, manufacturing, and field operations.”

About Crosspoint Capital
Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets. Crosspoint has assembled a group of successful operators, investors and sector experts to partner with foundational technology companies and drive differentiated returns. Crosspoint has offices in Menlo Park, CA and Boston, MA. For more information visit: www.crosspointcapital.com

About SynthBee, Inc.
SynthBee, Inc. is building safe, scalable, and reliable computing intelligence to amplify and accelerate human innovation. www.synthbee.com

Contact
[email protected]

SOURCE SynthBee, Inc.

MAGNOLIA, Texas, Feb. 4, 2026 — Stratus^® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.

The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis^™ basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS^® RF Multitined Expandable Electrode (Nimbus) design.

Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.

The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.

Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”

Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”

Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”

About Stratus Medical
Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.

About Wasatch Health Partners
Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.

Media Contact
Cody Jorgensen
Marketing Communications
Stratus Medical
346-703-0642
[email protected]
https://stratusmedical.com 

SOURCE Stratus Medical

MIDDLETON, Wis., Feb. 3, 2026 — Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences’ reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM^™ Antimicrobial Technology platform to minimize wound care complications.

To learn more about Imbed Biosciences and its innovative wound care technologies, please visit www.imbedbio.com.

“The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences,” said Terry Bromley, Imbed Biosciences CEO, “significantly expanding our reach of within the critical U.S. market, especially in the MD Office setting, and empowering us to further advance our technology platform, unique in its ability to integrate multiple therapeutic agents into a one-product solution to address unmet needs in wound care.”

Advancing Wound Care Solutions

This strategic investment enables Imbed Biosciences to further expand its product platform, designed to help achieve zero wound‑care complications, supported by a growing body of compelling clinical evidence. Imbed Biosciences holds a unique position in the skin substitute market, offering the only fully synthetic and antimicrobial solution of its kind. The investment from BioLab is centered around Imbed’s Microlyte^® product, which is focused on chronic wound indications and engineered for effective bioburden reduction as well as cell proliferation during the crucial “scaffolding” phase of healing.

“At BioLab, we invest in platforms that have the potential to elevate how clinicians approach wound care,” said Jaime Leija, president and CEO of BioLab Holdings. “Imbed’s SAM^™ technology represents a combination of scientific rigor, practical design, and long‑term scalability. We see tremendous opportunity to support its adoption in physician office settings, while helping accelerate solutions that simplify care delivery and improve outcomes for patients.”

The investment underscores a shared commitment to advancing patient outcomes in wound care through innovative, effective solutions. For details on BioLab Holdings Inc.’s announcement, refer to their press release.

Media Contact: Hillary Rush, VP Marketing, Email: [email protected]

About Imbed Biosciences
Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its SAM^™ Antimicrobial Technology. The company’s platform incorporates multiple therapeutic agents into ultra‑thin, biocompatible matrices that support skin regeneration in both chronic and acute wounds. Imbed’s expanding product portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the entire wound‑care continuum.

About BioLab Holdings, Inc.
BioLab Holdings, Inc. is a Phoenix-based medical manufacturer specializing in wound protection. Its products—including Membrane Wrap – Lite ^™ and Membrane Wrap ^™ use human tissue allograft derived from amniotic membrane to provide structural tissue for wound protection. BioLab’s mission is optimize the standard of care through innovations grounded in science, compassion, and collaboration.

SOURCE Imbed Biosciences